Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2023-02-14 4:45 pm Purchase |
2022-12-31 | 13G | BELLUS Health Inc. BLU |
RA Capital Management, L.P. | 12,452,574 9.900% |
2,222,300 (+21.72%) |
Filing History |
| 2023-02-14 4:45 pm Purchase |
2022-12-31 | 13G | Cogent Biosciences, Inc. COGT |
RA Capital Management, L.P. | 5,999,481 8.600% |
2,387,274 (+66.09%) |
Filing History |
| 2023-02-14 4:45 pm Purchase |
2022-12-31 | 13G | EyePoint Pharmaceuticals, Inc. EYPT |
RA Capital Management, L.P. | 3,408,706 9.990% |
1,801,847 (+112.13%) |
Filing History |
| 2023-02-14 4:45 pm Purchase |
2022-12-31 | 13G | Vaxcyte, Inc. PCVX |
RA Capital Management, L.P. | 8,153,559 9.990% |
4,287,751 (+110.91%) |
Filing History |
| 2023-02-14 4:45 pm Purchase |
2022-12-31 | 13G | Inhibrx Biosciences, Inc. INBX |
RA Capital Management, L.P. | 3,853,867 8.900% |
668,036 (+20.97%) |
Filing History |
| 2023-01-10 5:11 pm Purchase |
2023-01-06 | 13D | 89bio, Inc. ETNB |
RA Capital Management, L.P. | 6,159,054 17.960% |
1,854,607 (+43.09%) |
Filing History |
| 2023-01-06 4:30 pm Purchase |
2023-01-04 | 13G | Fulcrum Therapeutics, Inc. FULC |
RA Capital Management, L.P. | 9,686,628 18.600% |
2,686,628 (+38.38%) |
Filing History |
| 2022-12-30 4:57 pm Sale |
2022-12-28 | 13D | Achilles Therapeutics plc ACHL |
RA Capital Management, L.P. | 1,607,834 13.000% |
-1,369,109 (-45.99%) |
Filing History |
| 2022-12-30 4:30 pm Purchase |
2022-12-20 | 13G | Avidity Biosciences, Inc. RNA |
RA Capital Management, L.P. | 5,454,533 8.210% |
5,454,533 (New Position) |
Filing History |
| 2022-12-23 5:15 pm Sale |
2022-12-21 | 13D | Achilles Therapeutics plc ACHL |
RA Capital Management, L.P. | 2,976,943 13.000% |
-1,130,565 (-27.52%) |
Filing History |
| 2022-12-15 5:01 pm Sale |
2022-12-13 | 13D | Achilles Therapeutics plc ACHL |
RA Capital Management, L.P. | 4,107,508 13.000% |
-907,179 (-18.09%) |
Filing History |
| 2022-12-09 4:31 pm Purchase |
2022-12-07 | 13D | Vor Biopharma Inc. VOR |
RA Capital Management, L.P. | 22,760,145 34.800% |
11,628,845 (+104.47%) |
Filing History |
| 2022-12-05 5:12 pm Purchase |
2022-12-02 | 13D | Solid Biosciences Inc. SLDB |
RA Capital Management, L.P. | 3,431,618 17.570% |
2,601,760 (+313.52%) |
Filing History |
| 2022-12-02 4:30 pm Purchase |
2022-11-22 | 13G | NewAmsterdam Pharma Company N.V. NAMS |
RA Capital Management, L.P. | 4,333,333 5.290% |
4,333,333 (New Position) |
Filing History |
| 2022-11-28 4:31 pm Purchase |
2022-11-17 | 13D | Acrivon Therapeutics, Inc. Common Stock ACRV |
RA Capital Management, L.P. | 4,813,442 23.070% |
4,813,442 (New Position) |
Filing History |
| 2022-11-14 4:46 pm Purchase |
2022-11-10 | 13D | Vor Biopharma Inc. VOR |
RA Capital Management, L.P. | 11,131,300 28.780% |
10,327 (+0.09%) |
Filing History |
| 2022-11-14 4:43 pm Unchanged |
2022-11-14 | 13G | Standard BioTools Inc. LAB |
RA Capital Management, L.P. | 0 0.000% |
0 (Unchanged) |
Filing History |
| 2022-11-14 4:43 pm Sale |
2022-11-14 | 13G | LianBio LIANY |
RA Capital Management, L.P. | 0 0.000% |
-7,655,015 (Position Closed) |
Filing History |
| 2022-11-14 4:43 pm Sale |
2022-11-14 | 13G | Veru Inc. VERU |
RA Capital Management, L.P. | 0 0.000% |
-7,900,000 (Position Closed) |
Filing History |
| 2022-11-14 4:43 pm Sale |
2022-11-14 | 13G | Astria Therapeutics, Inc. ATXS |
RA Capital Management, L.P. | 0 0.000% |
-1,262,193 (Position Closed) |
Filing History |